EGFR and non-small cell lung carcinoma: In 2021, ESMO updated its guidelines to recommend adjuvant treatment with the targeted therapy osimertinib for adult patients with resected stage IB–IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R substitution mutations.13